I think what I would say to that is that there is a very ambitious agenda. We feel there is very good analytical evidence to suggest that once the measures that have been proposed are in place—and we just had draft regulations gazetted for the Patented Medicine Prices Review Board—they will lead to meaningful reductions in drug prices.
On December 7th, 2017. See this statement in context.